BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

...Ji, CEO of Elpiscience Biopharma Inc., also had one previous CEO position, at Boston-based New Paradigm...
BioCentury | Mar 19, 2021
Product Development

Pandemic response ushers in new era of biopharma data sharing: Guest Commentary

...spread around the world made it imperative that biopharmaceutical companies shift the research and development paradigm...
BioCentury | Mar 5, 2021
Tools & Techniques

Flexible platform: how NCI’s Sharpless thinks COVID variants could boost personalized therapies

As regulators embrace platform technologies to rapidly update COVID-19 vaccines, they are laying the groundwork for personalized cancer and rare disease therapies, according to NCI Director Ned Sharpless....
BioCentury | Mar 3, 2021
Product Development

Validation builds for Regeneron’s IgG antibodies in allergy

...lead the charge into a new treatment paradigm...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

...sits even further outside the clinical testing paradigm...
...“This is the major efficiency gain and paradigm...
BioCentury | Feb 20, 2021
Politics, Policy & Law

Creating access to cancer drugs in Africa

...The discounts are essential to change the paradigm...
...initiative and journey that is changing cancer paradigm...
BioCentury | Jan 29, 2021
Politics, Policy & Law

Advocates call for permanent FDA commissioner, line up behind Woodcock, Sharfstein

...“a strong leader with vision, passion, and experience,” and said that she “has innovated a paradigm...
BioCentury | Jan 23, 2021
Politics, Policy & Law

Biden memo freezes sunsets

...FDA to work with in this area.”Under FDA Commissioner Scott Gottlieb, FDA devised a new paradigm...
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

Becoming an essential pillar of the pandemic response has pushed the diagnostics industry toward more rapid and decentralized technologies, with a greater focus on routine asymptomatic screening. One year...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...round to assess whether a well-traveled CETP inhibitor can find a place in the treatment paradigm...
Items per page:
1 - 10 of 730
BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

...Ji, CEO of Elpiscience Biopharma Inc., also had one previous CEO position, at Boston-based New Paradigm...
BioCentury | Mar 19, 2021
Product Development

Pandemic response ushers in new era of biopharma data sharing: Guest Commentary

...spread around the world made it imperative that biopharmaceutical companies shift the research and development paradigm...
BioCentury | Mar 5, 2021
Tools & Techniques

Flexible platform: how NCI’s Sharpless thinks COVID variants could boost personalized therapies

As regulators embrace platform technologies to rapidly update COVID-19 vaccines, they are laying the groundwork for personalized cancer and rare disease therapies, according to NCI Director Ned Sharpless....
BioCentury | Mar 3, 2021
Product Development

Validation builds for Regeneron’s IgG antibodies in allergy

...lead the charge into a new treatment paradigm...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

...sits even further outside the clinical testing paradigm...
...“This is the major efficiency gain and paradigm...
BioCentury | Feb 20, 2021
Politics, Policy & Law

Creating access to cancer drugs in Africa

...The discounts are essential to change the paradigm...
...initiative and journey that is changing cancer paradigm...
BioCentury | Jan 29, 2021
Politics, Policy & Law

Advocates call for permanent FDA commissioner, line up behind Woodcock, Sharfstein

...“a strong leader with vision, passion, and experience,” and said that she “has innovated a paradigm...
BioCentury | Jan 23, 2021
Politics, Policy & Law

Biden memo freezes sunsets

...FDA to work with in this area.”Under FDA Commissioner Scott Gottlieb, FDA devised a new paradigm...
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

Becoming an essential pillar of the pandemic response has pushed the diagnostics industry toward more rapid and decentralized technologies, with a greater focus on routine asymptomatic screening. One year...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...round to assess whether a well-traveled CETP inhibitor can find a place in the treatment paradigm...
Items per page:
1 - 10 of 730